We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
101
Twist Bioscience
TWST
$5.7B
$2.4M 0.16%
+18,000
New +$2.09M
CEREW
102
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$2.38M 0.16%
165,295
-1,037
-0.6% -$5.2K
IPSC icon
103
Century Therapeutics
IPSC
$364M
$2.35M 0.16%
+80,000
New +$2.03M
LVTX
104
DELISTED
LAVA Therapeutics
LVTX
$2.34M 0.16%
215,359
+1,465
+0.7% +$18.2K
GLUE icon
105
Monte Rosa Therapeutics
GLUE
$1.4B
$2.27M 0.15%
+100,000
New +$2.04M
TMPM
106
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.17M 0.15%
219,440
– –
JYAC
107
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.98M 0.13%
199,028
– –
HCAQ
108
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$1.97M 0.13%
200,000
– –
HCCCU
109
DELISTED
Healthcare Capital Corp. Unit
HCCCU
$1.96M 0.13%
196,610
-203,390
-51% -$2.03M
ALDX icon
110
Aldeyra Therapeutics
ALDX
$92.9M
$1.7M 0.12%
+150,000
New +$1.8M
WIX icon
111
WIX.com
WIX
$2.3B
$1.66M 0.11%
5,700
– –
PLRX icon
112
Pliant Therapeutics
PLRX
$64.4M
$1.49M 0.1%
+51,000
New +$1.59M
OMIC
113
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.48M 0.1%
+1,796
New +$1.39M
CLRMU
114
DELISTED
Clarim Acquisition Corp. Unit
CLRMU
$1.48M 0.1%
148,886
-151,114
-50% -$1.5M
PRAX icon
115
Praxis Precision Medicines
PRAX
$8.58B
$1.38M 0.09%
+5,040
New +$1.8M
KA
116
DELISTED
Kineta, Inc. Common Stock
KA
$1.34M 0.09%
16,471
-13,330
-45% -$1.44M
TOI icon
117
The Oncology Institute
TOI
$486M
$1.26M 0.09%
126,491
-36,268
-22% -$365K
FLAC
118
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$1.24M 0.08%
126,687
– –
LFTR
119
DELISTED
Lefteris Acquisition Corp. Class A Common Stock
LFTR
$1.12M 0.08%
114,428
-5,572
-5% -$54.7K
CELC icon
120
Celcuity
CELC
$4.21B
$1.08M 0.07%
+45,000
New +$1.16M
OMEG
121
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$995K 0.07%
100,000
– –
MSPR
122
DELISTED
MSP Recovery Inc
MSPR
$986K 0.07%
23
– –
ETAC
123
DELISTED
E.Merge Technology Acquisition Corp. Class A Common Stock
ETAC
$976K 0.07%
100,000
– –
CMLTU
124
DELISTED
CM Life Sciences III Inc. Unit
CMLTU
$821K 0.06%
+75,000
New +$809K
LENZ
125
LENZ Therapeutics
LENZ
$166M
$767K 0.05%
+3,565
New +$621K
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.